NovaBay Pharmaceuticals Inc
NBY1.060USD
-0.040-3.64%
Cierre 11/04, 16:00（ET）Cotizaciones retrasadas 15 min
6.17MCap. mercado
2.66P/E TTM
Más Datos de NovaBay Pharmaceuticals Inc Compañía
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Información de NovaBay Pharmaceuticals Inc
Símbolo de cotizaciónNBY
Nombre de la empresaNovaBay Pharmaceuticals Inc
Fecha de salida a bolsaOct 26, 2007
Director ejecutivoMr. David E. Lazar
Número de empleados14
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 26
Dirección2000 Powell St Ste 1150
CiudadEMERYVILLE
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal94608-1804
Teléfono15108998800
Sitio Webhttps://novabay.com/
Símbolo de cotizaciónNBY
Fecha de salida a bolsaOct 26, 2007
Director ejecutivoMr. David E. Lazar
Ejecutivos de NovaBay Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+914.13%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-88.45%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-100.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Mr. Michael Kazley
Mr. Michael Kazley
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+914.13%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-88.45%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-100.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
9.78M
100.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
Estadísticas de accionistas
Actualizado: sáb., 18 de oct
Actualizado: sáb., 18 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Poplar Point Capital Management LLC
16.99%
C2C Wealth Management, LLC
1.63%
The Vanguard Group, Inc.
0.99%
Geode Capital Management, L.L.C.
0.56%
Rangeley Capital LLC
0.55%
Otro
79.28%
Accionistas
Accionistas
Proporción
Poplar Point Capital Management LLC
16.99%
C2C Wealth Management, LLC
1.63%
The Vanguard Group, Inc.
0.99%
Geode Capital Management, L.L.C.
0.56%
Rangeley Capital LLC
0.55%
Otro
79.28%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
18.04%
Investment Advisor
3.13%
Investment Advisor/Hedge Fund
0.56%
Venture Capital
0.34%
Individual Investor
0.09%
Otro
77.83%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
37
1.33M
22.07%
-126.95K
2025Q2
43
1.43M
24.52%
+210.59K
2025Q1
42
1.34M
22.96%
+376.59K
2024Q4
40
546.91K
11.19%
+390.20K
2024Q3
42
126.44K
2.60%
+79.02K
2024Q2
44
12.01K
0.89%
-33.08K
2024Q1
44
12.73K
1.48%
-22.10K
2023Q4
45
34.29K
18.48%
+25.73K
2023Q3
47
15.18K
15.11%
-444.00
2023Q2
47
9.53K
10.53%
-5.30K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Poplar Point Capital Management LLC
1.02M
16.99%
--
--
Sep 03, 2025
C2C Wealth Management, LLC
98.00K
1.63%
+43.00K
+78.18%
Jun 30, 2025
The Vanguard Group, Inc.
270.00
0%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
33.82K
0.56%
-1.17K
-3.35%
Jun 30, 2025
Rangeley Capital LLC
33.21K
0.55%
+33.21K
--
Jun 30, 2025
Two Sigma Investments, LP
24.28K
0.4%
+6.81K
+38.96%
Jun 30, 2025
XTX Markets LLC
20.31K
0.34%
+463.00
+2.33%
Jun 30, 2025
Tower Research Capital LLC
5.45K
0.09%
-6.00
-0.11%
Jun 30, 2025
UBS Financial Services, Inc.
3.38K
0.06%
+2.64K
+351.94%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Fecha
Tipo
Relación
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
